David Reese, Amgen R&D chief
August 7, 2022 08:02 AM EDTUpdated August 7, 08:27 PM
R&D
Pharma

In a fresh dis­ap­point­ment, Am­gen spot­lights a ma­jor safe­ty is­sue with KRAS com­bo

John Carroll

Editor & Founder

Am­gen had hoped that its lat­est study match­ing its land­mark KRAS G12C drug Lumakras with check­point in­hibitors would open up its treat­ment hori­zons and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times